Angelini Pharma is the pharmaceutical division of Angelini Group. The Group started almost 100 years ago as a small pharmaceutical laboratory, and over the years has grown into a leading international group in healthcare, present in Pharmaceuticals and Mass-Market.
Angelini Pharma is a leader in healthcare, with particular strength and expertise in the fields of Mental Health, including Pain, and Rare Diseases through its new Angelini Pharma Rare Diseases AG Business Unit dedicated to develop, manufacture and commercialize gaboxadol for the potential treatment of Angelman syndrome in Europe. The company is also a leading player in the Consumer Health segment, with highly successful OTC brands in Italy and abroad.
Angelini products are marketed in about 70 countries. The company operates directly in 15 countries employing more than 2.700 people, and commercializes its products in more than 50 countries through strategic alliances with leading international pharmaceutical groups.
As part of its internationalisation strategy, Angelini Pharma has also concentrated on development in countries with high growth potential.
Angelini Pharma reported a turnover of €902.5 million in 2019, about half accounted for by exports.
Angelini Pharma is an integrated pharmaceutical company, with an extensive R&D operation that has developed important molecules such as trazodone and benzydamine.
Current research focuses on Nervous System Diseases and Disorders, Pain and Inflammation and Rare Diseases, with a particular commitment to the research of new treatments for the paediatric population.
The research embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships both have an important role in creating innovation.
Angelini's “world class” production plants use cutting-edge technologies and have full certification for quality standards and respect for the environment.
In Italy, the Ancona plant produces finished pharmaceutical products and the industrial factory in Aprilia creates pharmaceutical raw materials, while disinfectants and sanitising products under the Amuchina brand are produced in Casella. These sites make extensive use of renewable energy sources and sustainability in general.
In March 2020 Angelini Pharma acquired the production plant in Albany (Georgia), a global supplier for ThermaCare Heatwrap.
Turnover 902 Million Euros
Angelini Pharma turnover more than tripled between 2000 and 2019, from €240.8m to €902.5m
Employees 2750 people
More than 190 researchers and 1,000 people in sales
Presence 70 Countries
Our products are marketed in about 70 countries. Direct presence in 15 countries.